Purpose Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth
factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-…

Antibody fragments of predetermined binding specificity have recently been constructed from
repertoires of antibody V genes, bypassing hybridoma technology and even immunization. …

We describe a process, based on display of antibodies on the surface of filamentous
bacteriophage, for selecting antibodies either by their affinity for antigen or by their kinetics of …

BACKGROUND: In this randomised phase III study (VEG105192; NCT00334282), pazopanib
previously demonstrated statistically and clinically meaningful improvement of progression-…

Background Non-clear cell renal cell carcinomas are histologically and genetically diverse
kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We …

Human peripheral blood lymphocytes can be transduced to express antigen-dependent
CD3ζ chimeric immune receptors (CIRs), which function independently of the T-cell receptor (…

The primary aim of this clinical trial was to determine the feasibility of delivering first-generation
CAR T cell therapy to patients with advanced, CEACAM5 + malignancy. Secondary aims …

This randomised, double-blind, placebo-controlled study was designed to evaluate the
ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong …

Chimeric Ag receptors (CARs) expressed in T cells permit the redirected lysis of tumor cells
in an MHC-unrestricted manner. In the Jurkat T cell model system, expression of a …

Purpose: Cytotoxic T lymphocyte antigen 4 (CTLA4), a key negative regulator of T-cell activation,
is targeted by the antibody tremelimumab to release potentially useful antitumor activity. …